Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Strychnine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.90 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.90 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.90 |
| ▸ | GLRA1 | P23415 | 14/20 | 0.90 |
| ▸ | GLRB | P48167 | 14/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.90 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.90 |
| ▸ | TAS2R46 | P59540 | 1/20 | 0.90 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Strychnine SCHEMBL27614772 | 0.99 | GLRA1 (0.91) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL25300604 | 0.96 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL27868128 | 0.96 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL29362678 | 0.95 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL21985190 | 0.95 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL29352583 | 0.95 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14117483 | 0.95 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL93798 | 0.95 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14029424 | 0.95 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14047653 | 0.95 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CONSTANCE THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240033312-A1 | CANNABIS OIL EXTRACTS AND COMPOSITIONS | CONSTANCE THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| US-11596618-B2 | Oral cannabinoid delivery formulations with mouthfeel experience enhancers | Resurgent Biosciences, Inc. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CHICAGO ATLANTIC ADMIN, LLC | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033312-A1 | CANNABIS OIL EXTRACTS AND COMPOSITIONS | CNR2, CNR1, DNER | SCN1A 4358/4885SCN2A 4572/4885SCN3A 4633/4885 |
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CNR1, CNR2, PROC | SCN1A 4311/4885SCN2A 4594/4885SCN3A 4534/4885 |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | MB, MLEC, NISCH | SCN1A 3777/4885SCN2A 2622/4885SCN3A 3060/4885 |
| US-11596618-B2 | Oral cannabinoid delivery formulations with mouthfeel experience enhancers | CNR2, CNR1, CPNE4 | SCN1A 4118/4885SCN2A 3655/4885SCN3A 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.